NCT03743272 is a clinical trial of LiverMultiScan in Liver Diseases, sponsored by Perspectum.

Who is sponsoring NCT03743272?

NCT03743272 is sponsored by Perspectum.

What drugs are being tested in NCT03743272?

Interventions in NCT03743272: LiverMultiScan.

What condition does NCT03743272 study?

NCT03743272 studies Liver Diseases, Primary Biliary Cirrhosis, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Cirrhosis, Hemochromatosis, Viral Hepatitis, Autoimmune Hepatitis, Primary Sclerosing Cholangitis.

Is NCT03743272 still recruiting?

NCT03743272 is currently completed. Last updated 1 December 2025.

Last reviewed 2025-12-01 · How we verify

NCT03743272

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Repeatability and Reproducibility of Multiparametric MRI

Completed Last updated 1 December 2025

What this trial tests

trial testing LiverMultiScan in Liver Diseases in 61 participants. Completed in 30 June 2024.

Timeline

3 June 2017

Primary endpoint
30 June 2024

30 June 2024

Quick facts

Lead sponsor	Perspectum
Status	Completed
Study type	OBSERVATIONAL
Enrollment	61
Start date	3 June 2017
Primary completion	30 June 2024
Estimated completion	30 June 2024
Sites	4 locations across United Kingdom, Netherlands

Drugs / interventions tested

LiverMultiScan

Conditions studied

Liver Diseases — all drugs for Liver Diseases →
Primary Biliary Cirrhosis — all drugs for Primary Biliary Cirrhosis →
Non-Alcoholic Fatty Liver Disease — all drugs for Non-Alcoholic Fatty Liver Disease →
Non-Alcoholic Steatohepatitis — all drugs for Non-Alcoholic Steatohepatitis →

Sponsor

Perspectum

Who can join

18 and older, any sex, with Liver Diseases or Primary Biliary Cirrhosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to prospectively assess the repeatability and reproducibility of iron-corrected T1 (cT1), T2\*, and hepatic proton density fat fraction (PDFF) quantification with multiparametric MRI using the LiverMultiScan™ (LMS, Perspectum Diagnostics, Oxford, UK) protocol across different field strengths, scanner manufacturers and models.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future.
Yip TC, Lyu F, Lin H, Li G, et al · · 2023 · cited 29× · PMID 36503204 · DOI 10.3350/cmh.2022.0426
Repeatability, Reproducibility, and Observer Variability of Cortical T1 Mapping for Renal Tissue Characterization.
Nowak M, Henningsson M, Davis T, Chowdhury N, et al · · 2025 · cited 4× · PMID 39468402 · DOI 10.1002/jmri.29602
Comparison of liver iron concentration calculated from R2* at 1.5 T and 3 T.
Pickles E, Kumar S, Brady M, Telford A, et al · · 2023 · cited 2× · PMID 36520162 · DOI 10.1007/s00261-022-03762-4

Verify or expand the search:

Other trials of LiverMultiScan

Trials testing the same drug.

NCT03165201 — Non-Invasive Rapid Assessment of Patients With Liver Transplants Using Magnetic Resonance Imaging With LiverMultiScan · completed
NCT03289897 — Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan · NA · completed

Other recruiting trials for Liver Diseases

Currently open trials in the same condition.

NCT07400289 — Development of a FibroScan Liver Examination Using a Single Probe · NA · recruiting
NCT07150624 — The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine · Phase 4 · recruiting
NCT06871111 — The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial · Phase 1 · recruiting
NCT06874296 — Assessing Declined Liver Grafts With Normothermic Machine Perfusion to Reduce Transplant Waiting Time · NA · recruiting
NCT07053488 — CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection · Phase 1, PHASE2 · recruiting

Other Perspectum trials

Trials by the same sponsor.

NCT07098650 — Haemdall: Developing a Quantitative MRI Biomarker of Infratentorial Superficial Siderosis of the Central Nervous System · recruiting
NCT04974710 — Developing an US-MRI Biomarker Fusion Model for Endometriosis · completed
NCT05326191 — First-trimester Placental Ultrasound Study · completed
NCT05000242 — West Hertfordshire Inflammatory Bowel Disease Technology Study · active not recruiting
NCT05110248 — Research and Development of Novel Quantitative Magnetic Resonance Imaging (MRI) Techniques in a Single Scan for Multiple · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03743272 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Perspectum
Last refreshed: 1 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03743272.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing